BioCentury
ARTICLE | Company News

Vertex moving into protein degradation with Kymera collaboration

May 15, 2019 6:51 PM UTC

In another move to expand its suite of modalities to address serious diseases, Vertex has partnered with Kymera to develop targeted small molecule protein degraders under a four-year deal.

Kymera Therapeutics LLC (Cambridge, Mass.) will use its Pegasus drug discovery platform and conduct research activities in multiple targets to identify clinical candidates for undisclosed diseases. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) has an option to exclusively license programs for up to six undisclosed targets. ...